Vor Biopharma Inc
$ 23.37
-1.27%
10 Aug - close price
- Market Cap 1,266,324,000 USD
- Current Price $ 23.37
- High / Low $ 23.84 / 22.95
- Stock P/E N/A
- Book Value -2.78
- EPS -69.30
- Next Earning Report 2026-08-11
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.70 %
- ROE -1.25 %
- 52 Week High 50.20
- 52 Week Low 6.50
About
Vor Biopharma, Inc., an early stage cell therapy company, develops hematopoietic stem cell (eHSC) therapies designed for cancer patients. The company is headquartered in Cambridge, Massachusetts.
Analyst Target Price
$37.88
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-08-11 | 2026-05-13 | 2026-03-30 | 2025-11-13 | 2025-08-12 | 2025-05-14 | 2025-03-20 | 2024-11-07 | 2024-08-08 | 2024-05-09 | 2024-03-20 | 2023-11-07 |
| Reported EPS | -0.8 | -0.73 | 307.53 | -121.63 | -251.2 | -5.2 | -0.44 | -8 | -8.2 | -9 | -0.39 | -9.8 |
| Estimated EPS | -0.69 | -0.78 | -1.191 | -4.1 | -11.8 | -4.16 | -0.3067 | -0.4 | -8.29 | -7.63 | -0.5 | -9.17 |
| Surprise | -0.11 | 0.05 | 308.721 | -117.53 | -239.4 | -1.04 | -0.1333 | -7.6 | 0.09 | -1.37 | 0.11 | -0.63 |
| Surprise Percentage | -15.942% | 6.4103% | 25921.1587% | -2866.5854% | -2028.8136% | -25% | -43.4627% | -1900% | 1.0856% | -17.9554% | 22% | -6.8702% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-11 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.69 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: VOR
2026-08-11 15:10:37
Vor Biopharma (NASDAQ:VOR) reported a Q2 loss of $0.80 per share, missing consensus estimates by $0.11. Shares closed down $0.39 at $22.98, though the stock remains well above its 52-week low. Analysts maintain a "Moderate Buy" rating with an average price target of $42.25, and institutional investors own 97.29% of the outstanding shares.
2026-08-11 14:10:37
Vor Biopharma Inc. has reported its financial results for the quarter that ended on June 30. The article, sourced from Reuters and aggregated by TradingView, provides an earnings summary for the biopharmaceutical company. Readers need unlimited access to TradingView to read the full report.
2026-08-11 13:10:36
Vor Biopharma Inc. reported a second-quarter 2026 net loss of $(62.8M) and diluted net loss per share of $(1.16), showing a significant improvement compared to the year-ago quarter. The company recorded no product revenue as it focuses on late-stage development programs, specifically advancing global Phase 3 trials for telitacicept with topline data expected in H1 2027. Vor Biopharma has also reallocated R&D spending and increased commercial activities in preparation for a potential product launch.
2026-08-11 09:10:37
Renaissance Technologies LLC has invested $2.30 million in Vor Biopharma Inc., acquiring 128,839 shares, while other institutional investors also increased their stakes, bringing total institutional ownership to 97.29%. Vor Biopharma is developing genome-edited cell therapies for blood cancers, with its lead candidate VOR33 in clinical trials. Analysts maintain a "Moderate Buy" rating with an average price target of $42.25, despite the stock trading down 1.3% recently.
2026-08-09 06:40:02
Eleven analysts have given Vor Biopharma Inc. (NASDAQ:VOR) a consensus rating of "Moderate Buy," with an average 12-month price target of $42.25. The stock opened at $23.67, with recent analyst actions including Jefferies upgrading it to "strong buy" and Wedbush raising its target price to $18. Institutional investors hold 97.29% of the shares, with significant increases from RA Capital Management and Fcpm III Services.
2026-08-07 22:11:01
FMR LLC and Abigail P. Johnson have each reported beneficial ownership of 12.0% of VOR Biopharma Inc.'s common stock, totaling 6,509,996 shares, according to a Schedule 13G/A filing. FMR LLC exercises sole voting power over most of these shares and sole dispositive power over all of them. The filing indicates that while other parties may have rights to dividends or sale proceeds, no single individual outside of the primary filers holds more than five percent of VOR Biopharma's outstanding common stock.
